3种新减肥药物-西替利司他（ATL-962）、利莫那班和赛尼可的研发与市场趋势  

Research and Development and Market Trends of three New Anti-obesity Drugs such as Cetilistat （ATL-962）, Rimonabant and Xenical

作　　者：阎家麒[1] 谢建平[1] 

机构地区：[1]泰州市今朝伟业精细化工有限公司

出　　处：《医药化工》2007年第3期38-39,共2页Pharmaceutical Chemicals

摘　　要：阐述了西替利司他、利莫那班和赛尼可3种新减肥药物的研发和市场趋势，并对这3种减肥药物作了疗效比较和优缺点分析。西替利司他和利莫那班蕴藏着巨大商机，尤其是脂肪酶抑制剂西替利司他。This paper presents the research and development of three new anti--obesity drugs such as Cetilitat （ATL-962）, Rimonabant and Xenical and their current market trends. Meanwhile, the three drugs effects in administration and the advantages and disadvantages of each was analyzed. Cetilitat （ATL-962）, Rimonabant have the potential to greatly enhance the market opportunity for lipase inhibitors and thus the potential for Cetilistat.

关 键 词：西替利司他 利莫那班 赛尼可 减肥药物 

分 类 号：TQ322.9[化学工程—合成树脂塑料工业]